Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6159606B2 - - Google Patents
[go: Go Back, main page]

JPS6159606B2 - - Google Patents

Info

Publication number
JPS6159606B2
JPS6159606B2 JP8468879A JP8468879A JPS6159606B2 JP S6159606 B2 JPS6159606 B2 JP S6159606B2 JP 8468879 A JP8468879 A JP 8468879A JP 8468879 A JP8468879 A JP 8468879A JP S6159606 B2 JPS6159606 B2 JP S6159606B2
Authority
JP
Japan
Prior art keywords
oil
suppository base
saturated
formula
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP8468879A
Other languages
Japanese (ja)
Other versions
JPS568326A (en
Inventor
Kenji Hara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP8468879A priority Critical patent/JPS568326A/en
Publication of JPS568326A publication Critical patent/JPS568326A/en
Publication of JPS6159606B2 publication Critical patent/JPS6159606B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は新規な坐剤基剤、更に詳細には次の一
般式(1) (式中、R1はCH3又はHを示し、R1がCH3のと
きR2はC11〜C15の飽和又は不飽和の炭化水素基
を、R1がHのときR2はC12〜C16の飽和又は不飽
和の炭化水素基を示し、Aは
The present invention provides a novel suppository base, more specifically, the following general formula (1): (In the formula, R 1 represents CH 3 or H, when R 1 is CH 3 , R 2 represents a C 11 to C 15 saturated or unsaturated hydrocarbon group, and when R 1 is H, R 2 represents C 12 to C16 saturated or unsaturated hydrocarbon group, A is

【式】 を示し、R3はC1〜C20の飽和もしくは不飽和の炭
化水素基又は(A)hHを示し、a,b,c,d,
e,f,g,hはその総和が1〜60の整数を示
す) で表わされるヒドロキシプロピルエーテル化グリ
コリピツドエステル(以下POSLと称する)を含
有する坐剤基剤に関する。 従来、基剤基剤としては、液状油性基剤、固体
油性基剤、固体水溶性基剤が使用されている。固
体油性基剤としては、ヤシ油、ラツカセイ油、オ
リーブ油、大豆油、ナタネ油、綿実油、ゴマ油、
トウモロコシ油、ヌカ油、ツバキ油、カカオ油、
豚油、羊毛脂、牛脂等の天然油脂類の水素添加
物、アセチル化物、分割抽出物や、高級脂肪酸と
グリセリンの合成エステル、高級脂肪酸と炭素数
2〜8のアルコールとの合成エステルが用いら
れ、これら基剤と薬物を主成分とし、界面活性剤
等を補助成分として配合して製造されている。 しかし、これらを種々組合せて得た坐剤は成分
が多岐にわたるため、均一な混合系となり難く、
保存時間の経過、保護環境の温度、湿度等の変化
によつて、相溶性の不均衡が発生し、発汗や粉ふ
き現象(ブルーミング)あるいはクラツキング等
を惹起し、外観上の品質の劣化をきたす等の欠点
があつた。 斯る実状において本発明者は上記欠点を解決せ
んと鋭意研究を行つた結果、その組成中に上記式
(1)で表わされるPOSLを配合すれば上記欠点のな
い優れた坐剤基剤が得られることを見出し、本発
明を完成した。 すなわち本発明は(1)式で表わされるPOSLを含
有する発汗、粉ふき現象がないと共にクラツキン
グを起さない坐剤基剤を提供するものである。 本発明で使用されるPOSLは新規化合物である
が、例えば次の一般式()、 (式中、R4はC1〜C20の飽和もしくは不飽和の
炭化水素基又は水素原子を示す) で表わされるグリコリピツド又はグリコリピツド
エステルにアルカリ触媒の存在下プロピレンオキ
サイドを反応させることにより製造される(特願
昭53−24306号参照)。 本発明で使用されるPOSLの代表的なものの性
質を示せば次のとおりである。
[Formula], R 3 represents a C 1 to C 20 saturated or unsaturated hydrocarbon group or (A) h H, a, b, c, d,
The present invention relates to a suppository base containing hydroxypropyl etherified glycolipid ester (hereinafter referred to as POSL) represented by: Conventionally, liquid oil bases, solid oil bases, and solid water-soluble bases have been used as base bases. Solid oil bases include coconut oil, peanut oil, olive oil, soybean oil, rapeseed oil, cottonseed oil, sesame oil,
Corn oil, bran oil, camellia oil, cacao oil,
Hydrogenated products, acetylated products, and fractionated extracts of natural fats and oils such as pork oil, wool fat, and beef tallow, synthetic esters of higher fatty acids and glycerin, and synthetic esters of higher fatty acids and alcohols with 2 to 8 carbon atoms are used. , these bases and drugs are the main ingredients, and surfactants and the like are added as auxiliary ingredients. However, since suppositories obtained by combining various of these materials have a wide variety of ingredients, it is difficult to obtain a homogeneous mixture.
Due to the passage of storage time and changes in the temperature, humidity, etc. of the protective environment, an imbalance in compatibility occurs, causing sweating, blooming, cracking, etc., resulting in a deterioration in the quality of the appearance. There were other drawbacks. Under such circumstances, the inventor of the present invention conducted intensive research to solve the above-mentioned drawbacks, and as a result, found that the above-mentioned formula
The present invention was completed based on the discovery that an excellent suppository base free from the above-mentioned drawbacks can be obtained by blending POSL represented by (1). That is, the present invention provides a suppository base containing POSL represented by formula (1) that is free from sweating and dusting phenomena and does not cause cracking. POSL used in the present invention is a new compound, for example, the following general formula (), (In the formula, R 4 represents a C 1 to C 20 saturated or unsaturated hydrocarbon group or a hydrogen atom) Produced by reacting glycolipid or glycolipid ester with propylene oxide in the presence of an alkali catalyst (See Japanese Patent Application No. 53-24306). Typical properties of POSL used in the present invention are as follows.

【表】 本発明の坐剤基剤は、当該組成物中にPOSLを
配合する以外は従来法と全く同様に製造すること
ができる。POSLの配合量は坐剤基剤中0.1〜10重
量%(以下単に%と記載する)、特に0.5〜8%配
合するのが好ましい。 次の本発明を実施例によつて示す。併せて
POSLの製造例を参考例として挙げる。 実施例 1 市販品である検体A〜C 下記の如き組成に従い通常の坐剤型を用い、溶
融法により作成した本発明品である坐剤基剤のみ
の検体D〜Gまた従来処方品である坐剤基剤のみ
の検体H,I、を10℃に4時間、続いて30℃、80
%R,H、に4時間保存した後、発汗の状況を目
視により観察を行なつた。 また、上記検体を30℃に8時間、続いて5℃に
24時間保存した後の粉ふき現象を目視により観察
した。これらの結果は、表の通りであり、本発明
に係る検体は発汗、粉ふき現象共に全く認められ
ず安定であつた。
[Table] The suppository base of the present invention can be produced in exactly the same manner as conventional methods, except for incorporating POSL into the composition. The amount of POSL to be blended is preferably 0.1 to 10% by weight (hereinafter simply referred to as %), particularly 0.5 to 8% by weight, in the suppository base. The following invention will be illustrated by way of examples. together
An example of manufacturing POSL is given as a reference example. Example 1 Samples A to C, which are commercially available products; Samples D to G, which have only a suppository base, which are products of the present invention prepared by the melting method using a normal suppository type according to the composition shown below; and samples D to G, which are conventionally formulated products. Specimens H and I, containing only suppository base, were heated to 10°C for 4 hours, then at 30°C and 80°C.
%R,H for 4 hours, the state of sweating was visually observed. In addition, the above specimen was heated to 30℃ for 8 hours, and then to 5℃.
After storage for 24 hours, the dusting phenomenon was visually observed. These results are shown in the table, and the specimens according to the present invention were stable with no sweating or dusting phenomenon observed.

【表】 参考例 (i) グルコース1500g、酵母エキス75g、尿素15
gに全量15となるように水を加え、殺菌し醗
酵液とする。この醗酵液に同一組成の培地で、
30℃、48時間培養したトルロプシス・ボンビコ
ーラを接種し、温度20℃、撹拌数300rpm、通
気量0.33VVMで醗酵を開始する。菌接種後24
時間培養したのち牛脂150gを加え以後24時間
間隔で同量の牛脂を合計900g加え、最後の添
加後更に24時間醗酵をおこない、合計168時間
醗酵を行つた。醗酵終了後醗酵槽の底部に沈降
したソホロリピツド相を傾斜過し、ソホロリ
ピツド1300gを得た。このものは水分を約50%
含有しており常温でペースト状である。 (ii) このソホロリピツド100gを、平均分子量200
のポリプロピレングリコール2.5gとともに200
ml容撹拌機つき丸底フラスコに取り、リービツ
ヒ冷却管を取りつけ、80℃油浴中撹拌下、250
mmHgの減圧下で水を留去した。約2時間で水
の留去は終了し、このときの水分は1%以下で
あつた。 (iii) このように調整されたソホロリピツドのポリ
プロピレングリコール溶液にメタノール150g
を加え、さらに硫酸を2.5g加えたのち40℃±
2℃の温度で90分間反応させた。反応はシリカ
ゲル薄層クロマトグラフ〔展開液:クロロホル
ム−メタノール−酢酸(75:20:5)〕で調べ
原料ソホロリピツドの多数のスポツトがグリコ
リピツドメチルエステルの一点に収れんした時
点で完了する。 反応終了後所定量の水酸化カリウムで中和、
過し、液を再びリービツヒ冷却管つき丸底
フラスコに入れ、メタノール及び酢酸メチルを
留去すれば茶色ペースト状の〔(2′−O−β−
D−グルコピラノシル−β−D−グルコピラノ
シル)オキシ〕アルカン酸及びアルケン酸メチ
ルエステルを94%含有するポリプロピレングル
コース共存物質48gが得られ、さらにシリカゲ
ルカラムクロマトグラフにより精製すれば純粋
な〔(2′−O−β−D−グルコピラノシル−β
−D−グルコピラノシル)オキシ〕アルカン酸
及びアルケン酸メチルエステルを得る。 IR(cm-1):1740(〓C=O エステル) 1380〜3200(−OH糖) 900〜750(グルコピラノース環) NMR〔δ(ピリジン)〕:1.1〜1.6(−CH2
CH2−) 3.6(−O−CH3) 3.5〜5.0(糖) 5.5(−CH=CH−不飽和脂肪酸) 油脂特数分析:酸価 0 水酸基価 615 ケン化価 88 エステル価 87 (iv) 上で得た〔(2′−O−β−D−グルコピラノ
シル−β−D−グルコピラノシル)オキシ〕ア
ルカン酸及びアルケン酸メチルエステルとポリ
プロピレングリコールの共存物100gを水酸化
カリウム0.25gをオートクレーブに採り、付加
モル数に対応するプロピレンオキサイドガスを
吹き込みながら100〜120℃で6時間反応させ
た。反応後リン酸で中和し、加圧別し、茶色
ペースト状の粗生成物を得、さらにシリカゲル
クロマトグラフにより精製すれば淡黄色ペース
ト状のポリオキシプロピレン〔(2′−O−β−
D−グルコピラノシル−β−D−グルコピラノ
シル)オキシ〕アルカン酸及びアルケン酸メチ
ルエステルを得た。
[Table] Reference example (i) Glucose 1500g, Yeast extract 75g, Urea 15
Add water to make a total volume of 15 g, sterilize it, and use it as a fermentation liquid. Add a medium of the same composition to this fermentation liquid,
Torulopsis bombicola cultured at 30℃ for 48 hours is inoculated, and fermentation is started at a temperature of 20℃, stirring rate of 300 rpm, and aeration rate of 0.33VVM. 24 days after bacterial inoculation
After culturing for an hour, 150 g of beef tallow was added, and the same amount of beef tallow was then added at 24 hour intervals for a total of 900 g. After the last addition, fermentation was continued for another 24 hours, for a total of 168 hours. After the fermentation was completed, the sophorolipid phase that had settled at the bottom of the fermenter was decanted to obtain 1300 g of sophorolipid. This stuff has about 50% water
It is paste-like at room temperature. (ii) 100g of this sophorolipid with an average molecular weight of 200
200 with 2.5g of polypropylene glycol
ml in a round bottom flask with a stirrer, attached a Liebig condenser, and stirred in an 80℃ oil bath at 250℃.
Water was distilled off under reduced pressure of mmHg. Distillation of water was completed in about 2 hours, and the water content at this time was 1% or less. (iii) Add 150 g of methanol to the polypropylene glycol solution of sophorolipid prepared in this way.
After adding 2.5g of sulfuric acid, the temperature was increased to 40℃±
The reaction was carried out for 90 minutes at a temperature of 2°C. The reaction is examined by silica gel thin layer chromatography (developing solution: chloroform-methanol-acetic acid (75:20:5)) and is completed when many spots of the raw material sophorolipid converge to one point on the glycolipid methyl ester. After the reaction is complete, neutralize with a predetermined amount of potassium hydroxide.
The liquid was poured into a round-bottomed flask with a Liebig condenser, and methanol and methyl acetate were distilled off to form a brown paste [(2'-O-β-
48 g of polypropylene glucose coexisting material containing 94% of D-glucopyranosyl-β-D-glucopyranosyl)oxy]alkanoic acid and alkenoic acid methyl ester was obtained, and further purification by silica gel column chromatography yielded pure [(2'-O -β-D-glucopyranosyl-β
-D-glucopyranosyl)oxy]alkanoic acid and alkenoic acid methyl ester are obtained. IR (cm -1 ): 1740 (〓C=O ester) 1380-3200 (-OH sugar) 900-750 (glucopyranose ring) NMR [δ (pyridine)]: 1.1-1.6 (-CH 2 -
CH 2 −) 3.6 (-O-CH 3 ) 3.5 to 5.0 (sugar) 5.5 (-CH=CH-unsaturated fatty acid) Oil and fat characteristic analysis: Acid value 0 Hydroxyl value 615 Saponification value 88 Ester value 87 (iv) 100 g of the coexistence of [(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]alkanoic acid and alkenoic acid methyl ester obtained above and polypropylene glycol was placed in an autoclave with 0.25 g of potassium hydroxide. The reaction was carried out at 100 to 120° C. for 6 hours while blowing propylene oxide gas corresponding to the number of moles added. After the reaction, the product was neutralized with phosphoric acid and separated under pressure to obtain a brown paste-like crude product, which was further purified by silica gel chromatography to give a pale yellow paste-like polyoxypropylene [(2'-O-β-
D-glucopyranosyl-β-D-glucopyranosyl)oxy]alkanoic acid and alkenoic acid methyl ester were obtained.

Claims (1)

【特許請求の範囲】 1 一般式(1) (式中、R1はCH3又はHを示し、R1がCH3のと
きR2はC11〜C15の飽和又は不飽和の炭化水素基
を、R1がHのときR2はC12〜C16の飽和又は不飽
和の炭化水素基を示し、Aは【式】 を示し、R3はC1〜C20の飽和もしくは不飽和の炭
化水素基又は(A)hHを示し、a,b,c,d,
e,f,g,hはその総和が1〜60の整数を示
す) で表わされるヒドロキシプロピルエーテル化グリ
コリピツドエステルを含有することを特徴とする
坐剤基剤。 2 ヒドロキシプロピルエーテル化グリコリピツ
ドエステルを組成物中に0.1〜10重量%配合する
ことを特徴とする特許請求の範囲第1項記載の坐
剤基剤。
[Claims] 1 General formula (1) (In the formula, R 1 represents CH 3 or H, when R 1 is CH 3 , R 2 represents a C 11 to C 15 saturated or unsaturated hydrocarbon group, and when R 1 is H, R 2 represents C 12 to C 16 saturated or unsaturated hydrocarbon group, A represents [Formula], R 3 represents C 1 to C 20 saturated or unsaturated hydrocarbon group or (A) h H, a, b, c, d,
A suppository base comprising a hydroxypropyl etherified glycolipid ester represented by 2. The suppository base according to claim 1, wherein 0.1 to 10% by weight of hydroxypropyl etherified glycolipid ester is blended into the composition.
JP8468879A 1979-07-04 1979-07-04 Suppository base Granted JPS568326A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8468879A JPS568326A (en) 1979-07-04 1979-07-04 Suppository base

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8468879A JPS568326A (en) 1979-07-04 1979-07-04 Suppository base

Publications (2)

Publication Number Publication Date
JPS568326A JPS568326A (en) 1981-01-28
JPS6159606B2 true JPS6159606B2 (en) 1986-12-17

Family

ID=13837609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8468879A Granted JPS568326A (en) 1979-07-04 1979-07-04 Suppository base

Country Status (1)

Country Link
JP (1) JPS568326A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02118706U (en) * 1989-03-10 1990-09-25

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02118706U (en) * 1989-03-10 1990-09-25

Also Published As

Publication number Publication date
JPS568326A (en) 1981-01-28

Similar Documents

Publication Publication Date Title
JPS6037087B2 (en) cosmetics
US4195177A (en) Hydroxyalkyl-etherified glycolipid ester
US4374776A (en) Sterol concentrates, the preparation thereof, and their use in the transformation of sterols by fermentation
JPH029436A (en) Surface active compound and method for its manufacture
US4510093A (en) Synthetic liquid wax esters
US4197166A (en) Dehydrating purification process for a fermentation product
US4305931A (en) Powdered compressed cosmetic material
EP0066107B1 (en) 2-hydroxy-3-methyl-branched-alkoxypropyl glyceryl ether and cosmetic composition containing same
JPS6137270B2 (en)
US6600060B2 (en) CLA-esters
US5646321A (en) Guerbet meadowfoam esters
JPS6159606B2 (en)
JPH06247956A (en) Ascorbic acid derivative
DE2558190A1 (en) 4-HYDROXYCYCLOPENT-2-EN-1-ON DERIVATIVES AND METHOD FOR THEIR PRODUCTION
FR2479222A1 (en) COMPOUND DERIVATIVES OF MONACOLIN K TYPE HAVING INHIBITORY ACTIVITY ON CHOLESTEROL BIOSYNTHESIS, PREPARATION METHOD AND THERAPEUTIC USE THEREOF
JPS61247390A (en) Production of partial ester of glycerine and condensed glycerine
US4305929A (en) Stick-shaped cosmetic material
US4201844A (en) Process for producing a hydroxyfatty acid ester
JP3143189B2 (en) Fragrance composition
JPS5941678B2 (en) Solid cleaning composition
JPH0749593B2 (en) Formulated perfume composition containing 2-cyclohexylpropionic acid or derivative thereof
Baer et al. Phosphonolipids. XX. Total synthesis of a naturally occurring ceramide aminoethylphosphonate and of its enantiomer
US2473406A (en) Diol compounds and esters thereof
FR2775686A1 (en) INDUSTRIAL AND COMMERCIAL EXPLOITATION OF CUTICULAR LIPIDS FROM GRAPE BAY IN PHARMACOLOGY AND COSMETOLOGY
JP2939650B2 (en) New sugar derivatives